Articles

Corevalve, VIV, valve in valve, FDA

The U.S. Food and Drug Administration (FDA) expanded the approved use of the CoreValve self-expanding transcatheter aortic valve replacement (TAVR) system to treat certain patients who have...

BioImage study, Mount Sinai, cardiovascular disease, ultrasound, CT, detection

Adding two non-invasive imaging tests to traditional cardiovascular disease risk factor assessment more precisely predicts a healthy patient’s future risk of heart attack, stroke, or premature...

TAVR, transcatheter heart valves, GlobalData, TMVR

Research and consulting firm GlobalData reported that the global market value for transcatheter heart valves will expand at a Compound Annual Growth Rate (CAGR) of 19.7 percent through 2020,...

Adding the antiplatelet drug ticagrelor (Brilinta) to aspirin as long-term therapy after a heart attack significantly reduced the rate of subsequent death from cardiovascular causes, heart attack...

Bendavia, heart attack, scarring, angioplasty, ACC, study

Patients who received the new drug Bendavia before undergoing angioplasty or stent implantation after a heart attack showed no significant reduction in scarring compared to patients given a...

Edwards Lifesciences, Sapien 3, Partner, ACC.15, acc 2015

he Sapien 3 heart valve (Edwards Lifesciences) demonstrated lower death, stroke and paravalvular leak rates than earlier generation devices in patients at high risk for surgery and showed...

BEST Trial

Despite the advent of a new generation of stents, patients with multiple narrowed arteries in the heart who received coronary artery bypass grafting fared better than those whose arteries were...

A novel therapy that would allow doctors to turn the body’s blood clotting ability off and on in a more controlled way was about as effective as established anticoagulants in patients undergoing...

Bonn Call for Action, FDA, radiation exposure, medical imaging, update

The U.S. Food and Drug Administration (FDA) announced its latest efforts in supporting the Bonn Call for Action, an international list of priorities for radiation protection in medicine for the...

Impella, FDA, high risk PCI, abiomed

The U.S. Food and Drug Administration (FDA) has granted pre-market approval (PMA) clearance for Abiomed’s Impella 2.5 heart pump during elective and urgent high-risk percutaneous coronary...